Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria by Miwa, Hiroto
© 2008 Miwa, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which 
permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2008:2 143–147 143
ORIGINAL RESEARCH
Prevalence of irritable bowel syndrome in Japan: 
Internet survey using Rome III criteria
Hiroto Miwa
Division of Upper Gastroenterology, 
Department of Internal Medicine, 
Hyogo College of Medicine, 
Nishinomiya, Hyogo, Japan
Correspondence: Hiroto Miwa
Division of Upper Gastroenterology, 
Department of Internal Medicine, Hyogo 
College of Medicine, 1-1 Mukogawa, 
Nishinomiya, Hyogo 663-8501, Japan
Tel +81 79 845 6665
Fax +81 79 845 6661
Email miwahgi@hyo-med.ac.jp
Objectives: We conducted a large-scale Internet survey of 10,000 subjects across Japan to 
determine irritable bowel syndrome (IBS) prevalence.
(J-ROAD: Japanese research of abdominal symptoms for IBS)
Methods: An equal number of male and female subjects, aged at least 20 years, were surveyed 
by questionnaire. The prevalence of IBS and its subtypes were determined using Rome III criteria, 
and the results were analyzed for gender- and age-related differences. IBS prevalence was also 
determined using Rome II criteria for comparison with Rome III criteria results.
Results: IBS prevalence based on Rome III criteria was 13.1%. IBS with diarrhea (IBS-D) 
subtype accounted for 29% of these cases, IBS with constipation (IBS-C) subtype 24% of cases, 
and mixed IBS (IBS-M) subtype 47% of cases. IBS-D was more common in men, while IBS-C 
predominated in women. IBS was most frequently associated with the 20–29 year age bracket, 
with prevalence decreasing with age. IBS prevalence based on Rome II criteria was 9.8%.
Conclusion: IBS prevalence based on Rome III criteria was 13.1%. On the other hand, IBS 
prevalence based on Rome II criteria was 9.8%. Diagnosis based on these updated criteria may 
uncover more IBS cases than Rome II criteria.
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Introduction
Irritable bowel syndrome (IBS) is one of the functional gastrointestinal disorders (FGIDs) 
characterized by gastrointestinal symptoms such as abdominal pain or discomfort, 
and alteration of bowel habits, despite the absence of organic disease (Drossman et al 
1994, 1997). IBS is a digestive disorder with high prevalence. Prevalence ranges from 
10 to 15% of the general population in major civilized countries, with incidence of 
1 to 2% annually (Talley 1999). IBS prevalence varies greatly according to gender. In 
the West, 2 to 4 times more women exhibit IBS than men (Chang et al 2002). Women 
have also been shown to be more prone to constipation-predominant IBS than men 
(Kang 2005). The syndrome generally develops in the late teens to 20s, with onset 
decreasing with age (Saito et al 2002).
In a small-scale epidemiological study conducted in Japan, IBS prevalence based 
on Rome II criteria was 14.2% (12.9% male, 15.5% female; N = 417) (Kanazawa et al 
2004). The largest-scale epidemiological study was conducted by Kumano and his col-
leagues (2004) and according to their study report, the IBS prevalence based on Rome II 
criteria was 6.1% (4.5% male, 7.8% female; N = 4,000). Compared with major western 
countries, the gender difference was low, while the prevalence was similar.
IBS is conventionally thought of as a neurotic disease. The establishment of 
the FGIDs concept in recent years has led to a growing need for the development 
of IBS diagnostic criteria. The Manning criteria (Manning et al 1978) were devel-
oped in 1978, followed by the Rome I criteria (Thompson et al 1992) in 1992. 
The latter was developed as a global diagnostic standard and underwent revision Patient Preference and Adherence 2008:2 144
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in 1999 due to its complex and difﬁ  cult application. The 
resulting Rome II criteria (Thompson et al 1999) were 
simple and practical, enabling their use in a large number 
of studies and clinical trials. Rome III criteria (Longstreth 
et al 2006) were announced in May 2006 and changed the 
required duration of symptoms from the “last 12 months” 
to the “past six months.” These criteria also classify the 
disease among four categories: IBS with diarrhea (IBS-
D), IBS with constipation (IBS-C), mixed IBS (IBS-M), 
unsubtyped IBS (IBS-U).
Here, we set out to conduct the ﬁ  rst large-scale IBS 
epidemiological study in Japan in accordance with Rome 
III criteria. The objectives of this study were (1) to determine 
IBS prevalence, subtype classiﬁ  cation, gender ratio, and 
age prevalence, as well as (2) to compare IBS prevalence 
estimates from the same study population based on Rome II 
criteria and Rome III criteria.
Materials and methods
Subjects
With the cooperation of Social Survey Research Information 
Co., Ltd. (Shinjuku, Tokyo), 10,000 general consumers from 
47 prefectures in Japan were selected as subjects using the 
stratiﬁ  ed random sampling method. All subjects were at least 
20 years of age and were stratiﬁ  ed into ﬁ  ve age categories 
(20s, 30s, 40s, 50s, 60 and above). Subjects consisted of 5,000 
males and 5,000 females, with each age group consisting of 
1,000 subjects. They were surveyed using the Internet begin-
ning from May 23, 2006 until May 30, 2006.
Questionnaires
Descriptions of symptoms in the questionnaire were prepared 
in accordance with IBS items in Rome III criteria due to the 
absence of a validated Japanese questionnaire. All questions 
were simpliﬁ  ed to enable the participants to understand 
the meaning of questions easily (Figure 1).
Diagnostic criteria
Subjects were categorized as having IBS based on Rome III 
and Rome II criteria (Figure 2). To meet the IBS classiﬁ  cation 
according to Rome II or III criteria, subjects must have 
had bowel habits that were consistent with each respective 
criterion, without meeting any exclusion criteria.
Rome III subtype classiﬁ  cation was performed as follows. 
Subjects affected mainly by “loose bowels/diarrhea” were 
classified into IBS-D. Those that were mainly affected 
by “constipation” were classiﬁ  ed into IBS-C, and those with 
both were considered to be IBS-M.
Results
The total IBS prevalence based on Rome III criteria was 
13.1% (1,309/10,000) (Table 1). The prevalence among 
women was 15.5% and that among men was 10.7%. 
Among the subjects who met Rome III criteria, 29% were 
categorized as having IBS-D, with this subtype being more 
common among males (male 47%, female 17%; Figure 3). 
Conversely, although 24% were classiﬁ  ed as having IBS-
C, the majority was female (male 9%, female 34%; Figure 
3). Forty-seven percent of subjects were classiﬁ  ed as hav-
ing IBS-M (male 44%, female 49%). The prevalence of 
the IBS-D was highest among males in their 20s (7.2%), 
and that of IBS-C was highest among females in their 20s 
(7.6%) (Figure 3).
The IBS prevalence based on Rome II criteria was 9.8%. 
Thus, revision to Rome III criteria increased this percentage 
by about 1.3 times. Incidentally, 7.1% of the subjects satisﬁ  ed 
both Rome II criteria and Rome III criteria, 6.0% satisﬁ  ed 
Rome III criteria only, 2.7% satisﬁ  ed Rome II criteria only, 
and 84.2% satisﬁ  ed neither of the two (Table 1).
Discussion
We conducted a large-scale, Internet-based epidemiological 
study investigating 10,000 general consumers across Japan 
according to Rome III criteria. As subjects were those 
registered on the Internet, one demerit was that doctors and 
other medical professionals were unable to directly assess 
them. Furthermore, generally speaking, some of the prob-
lems entailed by Internet surveys, compared to conventional 
interview surveys, are such as when respondents pretend to be 
someone they are not and when the selection of respondents 
is biased. For this study, we took some measures to prevent 
such problems; we asked the respondents their personal 
information (to prevent them from pretending to be someone 
they are not) while adopting a stratiﬁ  ed random sampling 
method by gender and age (to avoid any biased selection of 
respondents). Consequently, as many as 10,000 consumers 
nationwide were enrolled into the study, with each age group 
equally consisting of 1,000 subjects, and IBS prevalence was 
considered accurate. Actually, IBS prevalence was nearly 
consistent between the present study and IBS epidemiological 
studies conducted in Japan. As of 2004, two years before 
this questionnaire was performed, Internet use by those aged 
65 years or older was less than 50% (Ministry of Internal 
Affairs and Communications 2004), while use by those in 
their 20s to 40s exceeded 80%. Thus, Internet surveys are an 
appropriate means for collecting facts on IBS, a syndrome 
most frequently observed in younger generations.Patient Preference and Adherence 2008:2 145
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Figure 1 Questionnaire (n = 10,000).
Q1    Have you had any of the following symptoms in the 
last 3 months? (Multiple responses)
  1. Headache
  2. Head  feels  heavy
  3. Dizziness/Giddiness
  4. Ringing  ears
  5. Violent  sneezing
  6. Swelling
  7. Itchy  skin/Itchy  body
  8. Coughing
  9. Heart  ﬂ  utter/Palpitation
  10.  Nausea/Queasiness
  11.  Stomach  ache
  12.  Flatulence
  13.  Loose  bowels
  14.  Diarrhea
    15. Constipation (including hard stools)
  16.  Blood  in  stools
    17. Frequent toilet visits (urine)
  18.  Difﬁ  culty in urinating
  19.  ED/Erection  problems
    20. Loss of sex drive
    21. Cold hands and feet
  22.  Easily  tired/Lethargy
    23. Insomnia/Frequent waking at night
    24. Feel depressed/Lack of energy
  25.  Irritation
  26.  Inability  to  concentrate
  27.  Sleepy  in  the  daytime
    28. None of the above
Questions to respondents who answered “13. Loose bow-
els”, “14. Diarrhea”, or “15. Constipation (including hard 
stools)” in Q1.
If you answered “Loose bowels”, “Diarrhea” or “Constipation 
(including hard stools)” in Q1.
Q2    Which of the following most closely describes your 
symptoms (“Loose bowels”, “Diarrhea” or “Constipa-
tion (including hard stools)”)? 
  1. Mostly  “Loose  bowels/Diarrhea”
    2.   Both “Loose bowels/Diarrhea” and “Constipation”, 
but “Diarrhea” is more frequent
    3.   Both “Loose bowels/Diarrhea” and “Constipation”, 
but “Constipation” is more frequent
  4. Mostly  “Constipation”
Q3    When you have these symptoms (“Loose bowels”, 
“Diarrhea” or “Constipation (including hard stools)”), 
do you also have one of “Abdominal pain” or “Dis-
comfort”? 
    1.  One of “Abdominal pain” or “Discomfort”
    2.  Neither “Abdominal pain” nor “Discomfort”
Q4    How frequently do you have the symptom in question 
(“Loose bowels”, “Diarrhea” or “Constipation (includ-
ing hard stools)”)? Please answer each section.
Yes No
The symptom has appeared on three 
or more days per month in the last 
three months
12
The symptom appears for a total (Â1) of 90 
or more days in a year
12
The symptom is repeated for a month 
or more (Â2)
12
Â1  Even if the symptom is not continuous.
Â2    “Repeated” means that the symptom appears 
intermittently.
Q5    When did you ﬁ  rst start to be concerned about the 
symptom in question (“Loose bowels”, “Diarrhea” or 
“Constipation (including hard stools)”? 
    1.  Within the last month
    2.  About 3 months ago
    3.  About 6 months ago
    4.  About a year ago
    5.  About 2–3 years ago
    6.  About 4–9 years ago
    7.  At least 10 years ago
  8. Don’t  know/Can’t  remember
Q6    Do any of the following occur when you have the 
symptom in question (“Loose bowels”, “Diarrhea” or 
“Constipation (including hard stools)”)?
Yes No
Symptom eases after defecating 1 2
Frequency of defecation changes 1 2
Shape (hardness) of stools changes 1 2
Q7   Do you currently suffer from any ulcer, cancer or other 
disease in your stomach or intestines?
  1. Yes
  2. NoPatient Preference and Adherence 2008:2 146
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General consumers (n = 10,000)
Persons with abnormal bowel habits
•  General consumers with symptoms such as bad stomach, diarrhea, and constipation (including hard stool)
IBS* diagnostic items based on Rome III
A.   In the past three months, abdominal pain or 
discomfort has repeated for three or more 
days/month with two or more of the following 
changes:
    i) Symptoms improved with defecation
  ii)    Excretion frequency changed with onset of 
symptoms
    iii) Stool form (hardness) changed with onset
  *Patients started to experience symptoms six or 
more months ago, and met all of the above criteria 
in the past three months
Exclusive criteria (Red ﬂ  ag)
  Currently, no organic diseases such as ulcers and 
cancer are detected in the stomach or colon.
IBS* diagnostic items based on Rome II
B.   In the past 12 months,  abdominal pain or 
discomfort has developed (not necessarily 
continuously) for 90 or more days (12 weeks) 
with two or more of the following changes:
    i) Symptoms improved with defecation
  ii)    Excretion frequency changed with onset of 
symptoms
    iii) Stool form (hardness) changed with onset
Exclusive criteria (Red ﬂ  ag)
  Currently, no organic diseases such as ulcers and 
cancer are detected in the stomach or colon.
IBS subjects based on Rome III criteria IBS subjects based on Rome II criteria
Figure 2 Diagnostic items of irritable bowel syndrome.
Abbreviations: IBS, irritable bowel syndrome. 
Table 1 Number of subjects with IBS by IBS diagnostic criteria (%)
Diagnostic criteria  (n = 10,000)  95% conﬁ  dence interval
According to Rome III criteria  13.1% (1,309 persons)  12.4%–13.8%
According to Rome II criteria  9.8% (976 persons)  9.2%–10.3%
According to Rome II criteria and Rome III criteria  7.1% (706 persons)  6.6%–7.6%
According to Rome III criteria only  6.0% (603 persons)  5.6%–6.5%
According to Rome II criteria only  2.7% (270 persons)  2.4%–3.0%
Neither Rome II criteria nor Rome III criteria  84.2% (8,421 persons)  83.5%–84.9%
Abbreviations: IBS, irritable bowel syndrome.
The results of this study revealed that the total IBS 
prevalence in Japan is approximately 13.1%. Also, IBS 
prevalence based on Rome II criteria is 9.8%. Meanwhile, 
only 2.7% of the subjects satisfy Rome II criteria and 
this suggests that the prevalence rate was increased by the 
symptom duration being shortened from 12 months to 6 
months. Based on demographic data (as of November 1, 
2005) from the Bureau of Statistics, Japanese Ministry of 
Internal Affairs and Communications (2006), about 12 mil-
lion consumers are estimated to have IBS across the nation. 
Given that there are an estimated 16.2 million Japanese with 
actual and possible diabetes (Ministry of Health, Labour and Patient Preference and Adherence 2008:2 147
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Figure 3 Prevalence of IBS by subtype, gender, and age group according to Rome III 
criteria.
Welfare 2003), the illness is called a national afﬂ  iction of the 
Japanese. The results of our study conﬁ  rmed once again that 
the prevalence of IBS is very high as compared to diabetic 
data in Japan.
The prevalence of IBS among 5,000 males and 5,000 
females was 10.7% and 15.5%, respectively. Analysis based 
on the stratiﬁ  cation by age group revealed that, irrespective 
of gender, IBS was observed more frequently in younger 
populations. By subtype of the disease, IBS-D was more 
common among males and IBS-C among females. The former 
type of IBS is said to result in poorer QOL than the latter type 
(Kevin et al 2006). Given that there are more male patients 
with IBS-D in Japan, the impact on society is higher than 
in other countries.
In the past, as IBS excluded transient bowel habit prob-
lems caused by acute diseases such as gastroenteritis, it had 
to be set with a prolonged symptom duration (Thompson 
et al 1999). In this study, Rome III criteria were used for 
diagnosis. On the new diagnostic criteria, the symptom dura-
tion of IBS has been reduced to 6 months. IBS prevalence 
according to Rome III criteria increased about 1.3 times 
compared with Rome II criteria. The results suggest that 
diagnosis based on Rome III in the future may identify more 
IBS patients, who would not be given such a diagnosis with 
the older diagnostic criteria.
In conclusion, IBS prevalence based on Rome III criteria 
was 13.1%. On the other hand, IBS prevalence based on 
Rome II criteria was 9.8%. These results indicate an increase 
in the number of IBS patients due to the symptom duration 
being shortened to 6 months.
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